ArticleScientific reports2025
A data-driven machine learning framework to predict side effects of AstraZeneca and sinopharm COVID-19 vaccines.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Machine learning-assisted mRNA vaccine pharmacovigilance: a systematic review of multi-source real-world data.BMC medical informatics and decision making · 2026Pooled it
- Antiviral Efficacy, Cytotoxicity, Transcriptomics, and Discriminatory Function of 3D8 scFv Against Dengue and Zika Viruses.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Due to the widespread COVID-19 vaccinations, we are focusing more on side effects to immunizations that might affect people's perceptions, and ultimately vaccine hesitancy. Machine learning (ML)-based predictive models using individual-level data serve as robust tools for predicting such events. The objective of this study was to develop and evaluate machine learning models that could predict side effects using clinical and demographic characteristics from a public dataset after administering AstraZeneca and Sinopharm COVID-19 vaccines. The performance of ML models in predicting vaccine side effects varied across doses and types of side effects. For local side effects, SVM and GB excelled after the first dose (AUC = 0.77), while XGB and RF led after the second dose (AUC = 0.87), with SHAP analysis highlighting factors like age, symptom onset day, and vaccine type. Systemic side effects showed strong performance from SVM, GB, and LR for the first dose (AUC ~ 0.75-0.77), and LR and RF for the second dose (AUC = 0.80), influenced by factors such as first-dose effects and symptom duration. For total side effects, SVM, GB, and ANN performed best for the first dose (AUC = 0.82), while RF dominated for the second dose (AUC = 0.85), with SHAP analysis emphasizing symptom onset and prior dose effects. Machine learning models, specifically SVM and RF, have been demonstrated to provide promising and with reasonable accuracy in predicting COVID-19 vaccine adverse effects, including side effects. These predictive tools can support personalized vaccination strategies, enhance monitoring systems, and reduce public hesitancy by providing data-driven insights into post-vaccination responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.